Agenus

(NASDAQ) AGEN

Current Price$5.00

Market Cap$208.63M

Since IPO (2000)-100%

5 Year-95%

1 Year-25%

1 Month+69%

Agenus last closing stock price
Metric	Price	Date
Last close	USD 5.01	2026-07-17

Agenus stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+49.55%	USD 3.35	2026-07-10
1 month	+69.26%	USD 2.96	2026-06-17
3 month	+4.59%	USD 4.79	2026-04-17
Year to date	+59.55%	USD 3.14	2025-12-31
1 year	-25.45%	USD 6.72	2025-07-17
3 year	-85.35%	USD 34.20	2023-07-18
5 year	-95.26%	USD 105.78	2021-07-16
Since inception	-99.93%	USD 7,227.31	2000-02-04

Agenus Financials at a Glance

Market Cap

$208.63M

Revenue (TTM)

$123.87M

Net Income (TTM)

$64.61M

EPS (TTM)

$1.67

P/E Ratio

3.00

Dividend

$0.00

Beta (Volatility)

1.79 (High)

Dividend

$0.00

Beta (Volatility)

1.79 (High)

Price

$5.00

Volume

75,392

Open

$4.91

Price

$5.00

Volume

75,392

Open

$4.91

Previous Close

$5.00

Daily Range

$4.79 - $5.11

52-Week Range

$2.71 - $8.70

Estimated Earnings Date

Aug 10, 2026

Dividend

$0.00

Beta (Volatility)

1.79 (High)

Price

$5.00

Volume

75,392

Open

$4.91

Previous Close

$5.00

Daily Range

$4.79 - $5.11

52-Week Range

$2.71 - $8.70

Estimated Earnings Date

Aug 10, 2026

AGEN News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Agenus

Agenus develops medicines that help the immune system fight cancer. Its antibody therapies and vaccine ingredients support doctors treating difficult diseases. These products aim to improve options for patients with limited treatment choices.

What’s in the Agenus Toolbox?

Antibody Therapies: Medicines that help the immune system target cancer cells, mainly for hospitals and clinics.
Vaccine Adjuvants: Ingredients added to vaccines to boost their effectiveness, used by vaccine makers.
Cell Therapies: Treatments using special immune cells, focused on hard-to-treat cancers.
Discovery Platforms: Technology for finding new antibodies, used in research partnerships.
Collaborative Programs: Joint projects with other drug companies to develop and supply new therapies.

Growth Moves: Agenus on the Go

Sold manufacturing sites to Zydus Lifesciences in January 2026, shifting to outsourced production.
Formed supply and development partnerships with GSK, Merck, Incyte, and Zydus Lifesciences since 2024.
Expanded early access programs for key therapies in France and other countries in 2025-2026.
Deconsolidated MiNK Therapeutics in Q3 2025, now an equity investment.
Refocused pipeline in December 2024 to prioritize lead antibody programs and reduce costs.

Why Agenus Stands Out (Without the Cape)

Agenus focuses on immune-based cancer treatments, using its own research platforms and patent portfolio. Its main revenue comes from partnerships and royalties, not direct drug sales. The company adapts quickly, outsourcing manufacturing and narrowing its focus to core programs.

Five Things You Need to Know

Revenue was $30 million in Q3 2025, up 20.4% year-on-year.
Net loss improved to $5 million in Q3 2025 from $32 million in Q3 2024.
Gross profit reached $64 million in Q3 2025, up from a $66 million loss.
Cash used in operations was $15 million in Q3 2025, a 72.3% improvement.

Bottom Line

Agenus has shifted from in-house manufacturing to partnerships and narrowed its focus to key immune therapies. The company’s evolution shows adaptability and a drive to manage costs while advancing its core programs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Garo H. Armen, PhD

Website

www.agenusbio.com

Headquarters

Lexington, MA 02421-7305, US

AGEN Financials

Key Financial Metrics (TTM)

Gross Margin

52.14%

Operating Margin

6.62%

Net Income Margin

52.16%

Return on Equity

-23.05%

Return on Capital

-32.23%

Return on Assets

34.65%

Earnings Yield

33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$208.63M

Shares Outstanding

41.64M

Volume

75.39K

Avg. Volume

3.90M

Financials (TTM)

Gross Profit

$64.58M

Operating Income

$8.20M

EBITDA

$127.04M

Operating Cash Flow

-$87.53M

Capital Expenditure

-$1.00K

Free Cash Flow

-$87.53M

Cash & ST Invst.

$35.00M

Total Debt

$304.46M

Agenus Performance Analysis

Agenus annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 98,024,000	-66.8%
2023	2023-12-31	USD 156,314,000	59.5%
2024	2024-12-31	USD 103,463,000	-33.8%
2025	2025-12-31	USD 114,196,000	10.4%

Agenus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	6.8%
Q3	2025-09-30	17.7%
Q4	2025-12-31	13.1%
Q1	2026-03-31	-1.4%

Agenus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -15.64	641.5%
2023	2023-12-31	USD -13.75	-12.1%
2024	2024-12-31	USD -10.59	-22.9%
2025	2025-12-31	USD -0.00	-100.0%

Agenus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	2.9%
Q3	2025-09-30	294.0%
Q4	2025-12-31	-115.5%
Q1	2026-03-31	440.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$33.74M

+40.2%

Gross Profit

$33.15M

+1277.4%

Gross Margin

98.27%

N/A

Market Cap

$208.63M

N/A

Market Cap/Employee

$2.58M

N/A

Employees

N/A

Net Income

$39.23M

+255.3%

EBITDA

$54.48M

+625.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$35.00M

+89.3%

Total Debt

$304.46M

+230.8%

Accounts Receivable

$54.06M

+15171.8%

Inventory

$0.00

N/A

Long Term Debt

$163.81M

+88.7%

Short Term Debt

$140.65M

+2597.1%

Return on Assets

34.65%

N/A

Return on Invested Capital

-13.05%

N/A

Free Cash Flow

-$35.95M

-40.3%

Operating Cash Flow

-$35.95M

-40.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IRDOpus Genetics, Inc.

IRDOpus Genetics, Inc.$3.27-0.30%

TTRXTurn Therapeutics Inc.

TTRXTurn Therapeutics Inc.$9.12+1.00%

HURATuHURA Biosciences, Inc.

HURATuHURA Biosciences, Inc.$2.25+1.35%

ABOSAcumen Pharmaceuticals, Inc.

ABOSAcumen Pharmaceuticals, Inc.$2.25+3.69%

SEERSeer, Inc.

SEERSeer, Inc.$2.17+0.46%

FATEFate Therapeutics, Inc.

FATEFate Therapeutics, Inc.$2.78+1.83%

PLRXPliant Therapeutics, Inc.

PLRXPliant Therapeutics, Inc.$1.15+3.60%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

INTCIntel

INTCIntel$95.04-0.02%

PATHUiPath

PATHUiPath$12.15+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.53-0.05%

SKHYSK Hynix

SKHYSK Hynix$154.03+0.01%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$27.24-0.01%

Questions About AGEN

What is the current price of Agenus?

Agenus is trading at $5.00 per share.

What is the 52-week range for Agenus?

Over the past 52 weeks, Agenus has traded between $2.71 and $8.70.

How much debt does Agenus have?

As of the most recent reporting period, Agenus reported total debt of $304.46M.

How much cash does Agenus have on hand?

Agenus reported $35.00M in cash and cash equivalents in its most recent financial results.

What is Agenus’s dividend yield?

Agenus does not currently have a dividend yield.

Agenus

Agenus Financials at a Glance

AGEN News

Agenus Posts 48% Q2 Revenue Miss

3 Magnificent Growth Stocks to Buy Hand Over Fist

Up 40%: Is This Red-Hot Growth Stock Still a Buy?

Down 75%. Is Agenus Stock a Buy on the Dip?

Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

3 Magnificent Growth Stocks to Buy on the Dip

2 Low-Priced Stocks That Could Make You Richer

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Agenus

What’s in the Agenus Toolbox?

Growth Moves: Agenus on the Go

Why Agenus Stands Out (Without the Cape)

Five Things You Need to Know

Bottom Line

AGEN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Agenus Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AGEN

What is the current price of Agenus?

What is the 52-week range for Agenus?

How much debt does Agenus have?

How much cash does Agenus have on hand?

What is Agenus’s dividend yield?

Premium Investing Services